1.
Buccisano F, Palmieri R, Piciocchi A, Arena V, Maurillo L, Del Principe M-I, Paterno G, Irno-Consalvo M-A, Ottone T, Divona M, Conti C, Fraboni D, Lavorgna S, Arcese W, Voso MT, Venditti A. Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial. haematol [Internet]. 2022Mar.17 [cited 2022Dec.6];107(12):2823-3. Available from: https://haematologica.org/article/view/haematol.2021.279777